Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2017

Paul Song's Biography



Paul Song, Chief Medical Officer, Cynvenio Biosystems

Dr. Song oversees Cynvenio’s translational and clinical research programs. Dr. Song was formerly a member of the faculty at Cedars Sinai Medical Center, in the Samuel Oschin Cancer Center department of radiation oncology and biomedical sciences. In addition, he serves as Chief Medical Officer at AT-Gen Co. Ltd, where he oversees all clinical aspects of the company’s NK Vue, an ELISA-based blood test which measures natural killer cell activity. Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. Dr. Song completed his residency in radiation oncology at the University of Chicago and completed a brachytherapy fellowship at the Institut Gustave Roussy. He also was awarded an ASTRO research fellowship by the American Society of Radiation Oncology for his work in genetic radiotherapy.

Paul Song Image

The Role of Liquid Biopsies in Immunotherapy Selection and Monitoring

Thursday, 5 October 2017 at 16:00

Add to Calendar ▼2017-10-05 16:00:002017-10-05 17:00:00Europe/LondonThe Role of Liquid Biopsies in Immunotherapy Selection and MonitoringLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

This discussion highlights how liquid biopsy may better identify optimal timing of immunotherapy as well as serve as a way to monitor response.


Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com